Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial

Autor: Emmanuelle Bompas, Geraldine Martineau, Remy Delva, Isabelle Borget, Stéphane Culine, Giulia Baciarello, Groupe d’Etude des Tumeurs Uro-Genitales (Getug)., Charlotte Greilsamer, Philippe Barthélémy, Raffaele Ratta, Mathilde Deblock, Karim Fizazi, Florence Joly, Gwenaelle Gravis, Philippe Beuzeboc, Caroline Cheneau, J. F. Berdah, Youssef Tazi, Thierry Nguyen Tan Hon, Marine Gross-Goupil, Aude Flechon, Aline Maillard

Publikováno v: European Urology. 81:234-240

Background The taxanes docetaxel and cabazitaxel prolong overall survival for men with metastatic castration-resistant prostate cancer (mCRPC), with cabazitaxel approved in the postdocetaxel setting only. Recent data suggest they have similar efficac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc3f5f87bba3baaa685a8a0b058be50e
https://doi.org/10.1016/j.eururo.2021.10.016

Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group

Autor: Pierre-Emmanuel Stoebner, Christophe Bedane, A. Jannic, Marc Dumas, Marie Moncourier, Sandrine Mansard, Anne-Bénédicte Duval-Modeste, David Solub, Sophie Darras, Suzanne Devaux, Julia Sanchez, Nicolas Meyer, Laurent Misery, Valentine Heidelberger, Raoul Triller, Ingrid Kupfer-Bessaguet, Nathalie Beneton, Florence Brunet-Possenti, Gaëlle Quéreux, E. Maubec, Sophie Dalac, François Skowron, Safia Abed, Caroline Gaudy-Marqueste, Laurent Mortier, Monica Dinulescu, F. Herms, Lucie Peuvrel, Marouane Boubaya, Candice Hober, Pierre Guillet, Mahtab Samimi, Yves Reguerre, Nicolas Poulalhon, Anne Pham-Ledard, Stéphanie Catala, Eve-Marie Neidhardt, Romain Lesbazeilles, Jean-Philippe Arnault, Brigitte Dréno, Olivier Collard, Philippe Celerier, Julie De Quatrebarbes, Youssef Tazi, Pierre Combe, Caroline Jacobzone, Élodie Archier, F. Aubin, Dominique Spaeth, Clémence Berthin, Nora Kramkimel, Florent Grange, Candice Lesage, Lisa Fredeau, A. Schoeffler, Marc Pracht, Bertille Bonniaud, Laure Cesaire, Maxime Etienne, Olivier Lauche

Publikováno v: Cancers
Cancers, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Cancers, Vol 13, Iss 3547, p 3547 (2021)
Cancers, MDPI, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Volume 13
Issue 14

Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc71b63af8c9862b6ab08fc449cfdcd5
https://hal.inrae.fr/hal-03332168

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

Autor: Florence Joly, Frank Priou, S Roche-Forestier, C Foa, Benoit You, I.L. Ray-Coquard, Michel Fabbro, Anne Floquet, C. Roemer-Becuwe, Frédéric Selle, Laure Favier, P-E Heudel, A. Lesoin, Elsa Kalbacher, Alain Lortholary, A. Arnaud, Jérôme Meunier, Marie-Christine Kaminsky, Dominique Berton-Rigaud, Youssef Tazi, Isabelle Treilleux

Publikováno v: British Journal of Cancer

Backround: Patients with metastatic endometrial carcinoma have a poor prognosis and PIK3CA mutations and amplifications are common in these cancers. This study evaluated the efficacy and safety of the pure PI3K inhibitor BKM120 in advanced or recurre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09a05bdc8f53201f5704b8efa24a8d76
https://doi.org/10.1038/bjc.2016.430

Tratamiento médico del cáncer epitelial de ovario

Autor: Alexandra Leary, Catherine Lhommé, Youssef Tazi, Patricia Pautier

Publikováno v: EMC - Ginecología-Obstetricia. 51:1-5

La quimioterapia ocupa un lugar primordial en el tratamiento de los carcinomas ovaricos epiteliales, tanto en los estadios tempranos como en los avanzados. El esquema de referencia asocia carboplatino y paclitaxel por via intravenosa. En los estadios

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc64fe9727ff8e87654d34a242501fe9
https://doi.org/10.1016/s1283-081x(15)74752-1

Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC)

Autor: Thierry Nguyen Tan Hon, Isabelle Borget, J. F. Berdah, Remy Delva, Florence Joly, Youssef Tazi, Marine Gross-Goupil, Stéphane Culine, Aude Flechon, Tifenn Lharidon, Caroline Cheneau, Emmanuelle Bompas, Karim Fizazi, Gwenaelle Gravis, Philippe Beuzeboc, Geraldine Martineau, Christine Theodore, Giulia Baciarello, Philippe Barthélémy, Mathilde Deblock

Publikováno v: Journal of Clinical Oncology. 37:5017-5017

5017 Background: Docetaxel and cabazitaxel represent now the standard of care in men with mCRPC with similar efficacy reported in metastatic first-line setting in the FIRSTANA phase 3 trial. We assessed patients’ preference between the two taxanes.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::30a0d31d9647904a7f3927004b311777
https://doi.org/10.1200/jco.2019.37.15_suppl.5017